On Dec. 31, 2012, the U.S. Food and Drug Administration (FDA) approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy; it is the first FDA-approved therapy for the indication. Derived from the red sap of the Croton lechleri plant, Fulyzaq is the second botanical prescription drug approved by FDA. Read more.
